This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
4. References
Alam, Z.I., Daniel, S.E., et al., 1997, A generalised increase in protein carbonyls in the brain in Parkinson’s but not incidental Lewy body disease, J. Neurochem. 69:1326–1329.
Alam, Z.I., Jenner, A., et al., 1997, Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra, J. Neurochem. 69:1196–1203.
Ben-Shachar, D.Z.R., and Glinka, Y., 1995, Dopamine neurotoxicity: inhibition of mitochondrial respiration, J. Neurochem. 64:718–723.
Betarbet, R., Sherer, T.B., et al., 2000, Chronic systemic pesticide exposure reproduces features of Parkinson’s disease, Nat. Neurosci. 3:1301–1306.
Bonifati, V., Rizzu, P., et al., 2003, Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism, Science 299:256–259.
Bowyer, J.F., and Weiner, N., 1987, Modulation of the Ca++-evoked release of [3H]dopamine from striatal synaptosomes by dopamine (D2) agonists and antagonists, J. Pharmacol. Exp. Ther. 241:27–33.
Bunney, B.S., Aghajanian, G.K., et al., 1973, Comparison of effects of L-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic neurones, Nat. New Biol. 245:123–125.
Cass, W.A., and Zahniser, N.R., 1990, Inhibition of striatal dopamine release by the selective D-2 dopamine receptor agonist N-0437 is blocked by quinine, Synapse 5:336–337.
Conway, K.A., Harper, J.D., et al., 1998, Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease, Nat. Med. 4:1318–1320.
Dexter, D.T., Carter, C.J., et al., 1989, Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease, J. Neurochem. 52:381–389.
El-Agnaf, O.M., Jakes, R., et al., 1998, Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments, FEBS Lett. 440:71–75.
el Mestikawy, S., Glowinski, J., et al., 1986, Presynaptic dopamine autoreceptors control tyrosine hydroxylase activation in depolarized striatal dopaminergic terminals, J. Neurochem. 46:12–22.
Finkelstein, D., Parish, C.L., Stanic, D., Borrelli, E., Drago, J., and Horne, M.K., 2001, The role of Dopamine Receptors in regulating the size of axonal arbours, In: The Basal Ganglia VII. Eds. Nicholson L. and Faull R. Kluwer Academic/Plenum Publishers. 313–322.
Finkelstein, D.I., Stanic, D., et al., 2000, Axonal sprouting following lesions of the rat substantia nigra, Neuroscience 97:99–112.
Floor, E., and Wetzel, M.G., 1998, Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem. 70:268–275.
Gassen, M., Glinka, Y., Pinchasi, B., and Youdim, M.B., 1996, Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction, Eur. J. Pharmacol. 308:219–225.
Giasson, B.I., Duda, J.E., et al., 2000, Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions, Science 290:985–989.
Glinka, Y., Gassen, M., and Youdim, M.D., 1997, Mechanism of 6-hydroxydopamine neurotoxicity. J. Neural. Transm. Suppl. 50:55–66.
Glinka, Y., Tipton, K.F., and Youdim, M.B., 1998, Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine, Eur. J. Pharmacol. 351:121–129.
Glinka, Y., and Youdim, M.D., 1995, Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur. J. Pharmacol. 292:329–332.
Goedert, M., 2001, Alpha-synuclein and neurodegenerative diseases, Nat. Rev. Neurosci. 2:492–501.
Goldberg, M.S., and Lansbury, P.T., Jr., 2000, Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson’s disease? Nat. Cell Biol. 2:E115–E119.
Graham, D.G., Tiffany, S.M., et al., 1978, The toxicity of melanin precursors, J. Invest. Dermatol. 70:113–116.
Hashimoto, M., Hsu, L.J., et al., 1998, Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease, Brain Res. 799:301–306.
Hashimoto, M., Takeda, A., et al., 1999, Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease, J. Biol. Chem. 274:28849–28852.
Healy, D.G., Abou-Sleiman, P.M., et al., 2004, PINK, PANK, or PARK? A clinicians’ guide to familial parkinsonism, Lancet Neurol. 3:652–662.
Hersch, S.M., Ciliax, B.J., et al., 1995, Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents, J. Neurosci. 15:5222–237.
Hsu, L.J., Sagara, Y., et al., 2000, alpha-synuclein promotes mitochondrial deficit and oxidative stress, Am. J. Pathol. 157:401–410.
Jenner, P., 1998, Oxidative mechanisms in nigral cell death in Parkinson’s disease, Mov. Disord. 13Suppl 1:24–34.
Kanda, S., Bishop, J.F., et al., 2000, Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation, Neuroscience 97:279–284.
Kimmel, H.L., Joyce, A.R., et al., 2001, Dopamine D1 and D2 receptors influence dopamine transporter synthesis and degradation in the rat, J. Pharmacol. Exp. Ther. 298:129–140.
Lacey, M.G., Mercuri, N.B., et al., 1987, Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta, J. Physiol. 392:397–416.
Langston, J.W., and Ballard, P.A., Jr., 1983, Parkinson’s disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, New Eng. J. Med. 309:310.
Lee, H.J., and Lee, S.J., 2002, Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells, J. Biol. Chem. 277:48976–48983.
Lindgren, N., Xu, Z.Q., et al., 2001, Dopamine D(2) receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum, Eur. J. Neurosci. 13:773–780.
Lotharius, J., Barg, S., et al., 2002, Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line, J. Biol. Chem. 277:38884–38894.
Lotharius, J., and Brundin, P., 2002, Pathogenesis of Parkinson’s disease: dopamine, vesicles and alpha-synuclein, Nature Rev. Neurosci. 3:932–942.
Lotharius, J., and Brundin, P., 2002, Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson’s disease, Human Mol. Genet. 1:2395–2407.
Maker, H.S., W.C., Silides, D.J., and Cohen, G., 1981, Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates, J. Neurochem. 36:589–593.
Narhi, L., Wood, S.J., et al., 1999, Both familial Parkinson’s disease mutations accelerate alpha-synuclein aggregation, J. Biol. Chem. 274:9843–9846.
Onali, P., Olianas, M.C., et al., 1988, Evidence that adenosine A2 and dopamine autoreceptors antagonistically regulate tyrosine hydroxylase activity in rat striatal synaptosomes, Brain Res. 456:302–309.
Palacino, J.J., Sagi, D., et al., 2004, Mitochondrial dysfunction and oxidative damage in parkin-deficient mice, J. Biol. Chem. 279:18614–18622.
Parish, C.L., Finkelstein, D.I., et al., 2001, The role of dopamine receptors in regulating the size of axonal arbors, J. Neurosci. 21:5147–5157.
Parish, C.L., Stanic, D., et al., 2002, Effects of long-term treatment with dopamine receptor agonists and antagonists on terminal arbor size, Eur. J. Neurosci. 16:787–794.
Petersen, A., Puschban, Z., Lotharius, J., et al., 2002, Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington’s disease mice, Neurobiol. Dis. 11:134–146.
Polymeropoulos, M.H., Lavedan, C., et al., 1997, Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease, Science 276:2045–2047.
Robinson, M.B., 2002, Regulated trafficking of neurotransmitter transporters: common notes but different melodies, J. Neurochem. 80:1–11.
Saggu, H., Cooksey, J., et al., 1989, A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra, J. Neurochem. 53:692–697.
Singleton, A.B., Farrer, M., et al., 2003, alpha-Synuclein locus triplication causes Parkinson’s disease, Science 302:841.
Sofic, E., Riederer, P., et al., 1988, Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain, J. Neural. Transm. 74:199–205.
Spillantini, M.G., Crowther, R.A., et al., 1998, alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies, Proc. Natl. Acad. Sci. USA 95:6469–6473.
Stanic, D., Finkelstein, D.I., et al., 2003a, Time course of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat, Eur. J. Neurosci. 18:1175–1188.
Stanic, D., Parish, C.L., et al., 2003b, Changes in function and ultrastructure of striatal dopaminergic terminals that regenerate following partial lesions of the SNpc, J. Neurochem. 86:329–343.
Tepper, J.M., Nakamura, S., et al., 1984, Autoreceptor-mediated changes in dopaminergic terminal excitability: effects of striatal drug infusions, Brain Res. 309:317–333.
Tompkins, M.M., Basgall, E.J., et al., 1997, Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons, Am. J. Pathol. 150:119–131.
Tompkins, M.M., and Hill, W.D., 1997, Contribution of somal Lewy bodies to neuronal death, Brain Res. 775:24–29.
Ungerstedt, U., Herrera-Marschitz, M., et al., 1982, Models for studying the synaptic mechanisms: correlative measurements of transmitter release and drug altered behaviour. In: Behavioural Models and the Analysis of Drug Action. Eds: M.Y. Spiegelstein and A. Levy. Amsterdam, Elsevier: 57–70.
Valente, E.M., Abou-Sleiman, P.M., et al., 2004, Hereditary early-onset Parkinson’s disease caused by mutations in PINK1, Science 304:1158–1160.
Xu, J., Kao, S.Y., et al., 2002, Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease, Nat. Med. 8:600–606.
Zhang, Y., Dawson, V.L., et al., 2000, Oxidative stress and genetics in the pathogenesis of Parkinson’s disease, Neurobiol. Dis. 7:240–250.
Zigmond, M., Hastings, T., et al., 2002, Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity? Parkinsonism Relat. Disord. 8:389.
Zigmond, M.J., Abercrombie, E.D., et al., 1990, Compensations after lesions of central dopaminergic neurons: some clinical and basic implications, Trends Neurosci. 13:290–296.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this paper
Cite this paper
Nunan, J. et al. (2005). Spontaneous Formation of Lewy Bodies in a Rodent. In: Bolam, J.P., Ingham, C.A., Magill, P.J. (eds) The Basal Ganglia VIII. Advances in Behavioral Biology, vol 56. Springer, Boston, MA. https://doi.org/10.1007/0-387-28066-9_30
Download citation
DOI: https://doi.org/10.1007/0-387-28066-9_30
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-28065-3
Online ISBN: 978-0-387-28066-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)